RARRES2

Across TCGA pan-cancer cohorts, RARRES2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RARRES2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where RARRES2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RARRES2 is over-expressed in tumor, although a few such as LUAD and COAD show the opposite, repressed pattern.

LUAD, COAD, and HNSC are the cancer types where RARRES2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RARRES2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	−0.666	<.001	9	view →
COAD	Female	All	−0.564	<.001	9	view →
HNSC	Male	IV	−0.808	<.001	8	view →
LSCC	Female	All	−0.594	<.001	8	view →
CCRCC	Male	III,IV	−0.508	<.001	6	view →
PDAC	Male	All	+0.873	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RARRES2–LUAD

Open the LUAD breakdown →